CAMBRIDGE, Mass., July 31, 2012 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced that it has commenced an underwritten registered public offering of $150 million of its common stock. All of these shares are being sold by Idenix.
